LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE Drug Patent Profile

When do Lamivudine, Nevirapine And Zidovudine patents expire, and what generic alternatives are available?

Lamivudine, Nevirapine And Zidovudine is a drug marketed by Micro Labs and is included in one NDA.

The generic ingredient in LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.

Summary for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE	lamivudine; nevirapine; zidovudine	TABLET;ORAL	205626-001	Aug 13, 2018		DISCN	Yes	No

Investment Scenario and Fundamentals Analysis for Lamivudine, Nevirapine, and Zidovudine

Last updated: February 3, 2026

Market Overview

Lamivudine, Nevirapine, and Zidovudine are antiretroviral drugs (ARVs) commonly used in combination therapies for HIV treatment. Global HIV/AIDS treatment demand drives their commercial viability. The ARV market reached approximately $20 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5-7% through 2030, driven by increasing access in developing countries and ongoing R&D efforts for improved formulations [1].

Product Profiles and Competitive Landscape

Drug	Class	Formulations	Patent Status	Key Marketed Brands	Bioequivalence & Generics
Lamivudine	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	Tablets, Solution	Patent expired in major markets (e.g., US 2016)	Epivir	Widely available as generic; high market penetration
Nevirapine	Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)	Tablets	Patent expired in 2013 (US)	Viramune	Off-patent; significant generic competition
Zidovudine	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	IV, Tablets	Patent expired in 2004 (US)	Retrovir	Generic versions dominate; low barriers to entry

R&D and Regulatory Status

• Lamivudine: Approved globally; combination with other ARVs is standard. Ongoing studies focus on long-acting formulations.
• Nevirapine: Approved since 1996; phase II and III studies investigate safety in specific populations.
• Zidovudine: Established since the 1980s; primarily used in generic form today. Limited development pipeline.

Commercial Dynamics and Key Considerations

Patent and Patent Expiration

The expiration of patents for lamivudine, nevirapine, and zidovudine in major markets reduces barriers for generic manufacturers, intensifying price competition.

Market Trends

• Increased adoption of fixed-dose combinations (FDCs) consolidates market share.
• Growing access in sub-Saharan Africa supports volume expansion.
• Resistance patterns favor newer agents, but first-generation drugs maintain roles in treatment regimens.

Manufacturing and Supply Chain

• Established manufacturing bases in India and China provide cost advantages.
• Supply chain disruptions affecting raw materials or regulatory delays can impact availability.

Regulatory Risks

• Patent litigation and regulatory hurdles remain in emerging markets.
• Slow approval processes for new formulations or biosimilars restrict market expansion.

Competitive Threats

• Entry of newer drugs with improved safety profiles (e.g., integrase inhibitors) may marginalize older drugs.
• Price erosion due to generics challenges profitability for branded versions.

Investment Outlook

• Short-term: Declining revenues in developed markets due to patent expiry but stable demand in emerging markets.
• Long-term: Growth depends on pipeline expansion, formulation innovation, and regional market penetration.

Financial and Strategic Indicators

Indicator	Observation
Revenue	Declining in mature markets; stable or growing in Africa and Asia
Gross Margin	~60% for branded; >90% for generics
R&D Investment	Low for established molecules; focus shifts to line extensions and formulations
Market Penetration	High in low-income regions; limited in high-income markets post-patent expiry

Risks and Opportunities

Risks

• Patent cliffs leading to commoditization.
• Emergence of resistance impacting drug utility.
• Regulatory barriers delaying launches in key markets.

Opportunities

• Development of long-acting injectables/traditional formulations.
• Combination drug regimens offering improved compliance.
• Expansion into new markets with increasing HIV prevalence.

Strategic Recommendations

• Leverage existing manufacturing efficiency for cost leadership.
• Invest in formulation technologies (e.g., injectables) to extend product life cycles.
• Pursue partnerships or licensing to access newer markets.
• Monitor resistance trends and shift focus towards drugs with better safety profiles.

Key Takeaways

1. The core drugs have patents primarily expired, leading to commoditization and intense generic competition.
2. Growing demand in emerging markets supports volume-based opportunities.
3. Innovation in delivery systems and formulations presents potential for differentiation.
4. Cost advantages from established manufacturing are critical.
5. Regulatory and patent landscapes will influence market access strategies.

FAQs

1. What is the primary driver of demand for lamivudine, nevirapine, and zidovudine?
   The global HIV/AIDS patient population, especially in developing regions, and the adoption of combination regimens sustain demand.

2. How does patent expiration affect market prospects?
   Patent expiry leads to generic competition, reducing prices and margins but increasing volume through broader access.

3. Are newer agents replacing these drugs?
   Yes, drugs like integrase inhibitors offer improved safety and tolerability, though older drugs remain foundational in many treatment programs.

4. What regulations influence their market penetration?
   WHO prequalification, national regulatory approvals, and patent laws in target countries shape availability and pricing.

5. What strategies can manufacturers pursue post-patent?
   Focus on formulation innovations, cost leadership, and expanding into underserved markets with high HIV prevalence.

References

[1] IQVIA, "The Global HIV Market," 2022.